US 12,006,550 B2
Targeting treatment for ADAM30 in pathological cells
Wenbin Tan, Columbia, SC (US); Elaine G. Taine, Columbia, SC (US); Hui Wang, Wuhan (CN); Vi Nguyen, Columbia, SC (US); and Xiaoling Cao, Columbia, SC (US)
Assigned to University of South Carolina, Columbia, SC (US)
Filed by University of South Carolina, Columbia, SC (US)
Filed on Aug. 12, 2021, as Appl. No. 17/400,308.
Claims priority of provisional application 63/090,382, filed on Oct. 12, 2020.
Prior Publication US 2022/0112559 A1, Apr. 14, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6883 (2018.01); C07K 16/28 (2006.01)
CPC C12Q 1/6883 (2013.01) [C07K 16/2896 (2013.01); C07K 2317/76 (2013.01); C12Q 2600/158 (2013.01)] 4 Claims
 
1. Methods for detecting congenital vascular malformations comprising:
obtaining at least one body fluid sample from a subject;
introducing at least one human or humanized antibody having at least two binding specificities for at least two different antigens to the at least one body fluid sample wherein the at least one human or humanized antibody compound is configured to bind to at least one domain of at least one biomarker comprising an ADAM30 protein or polypeptide thereof present in the at least one body fluid sample;
wherein binding of the at least one human or humanized antibody to the at least one domain of the at least one biomarker forms an assay;
wherein the presence of the at least one biomarker in the body fluid, whether analyzed in vivo or in vitro, indicates a vascular disease or disorder associated with aberrant ADAM30 expression or activity in the subject; and
wherein formation of the assay determines when there is an increase in ADAM30 to administer a therapeutically effective amount of a therapeutic agent to treat the vascular disease or disorder.